|  E88 |  | Other and unspecified metabolic disorders   | 
	
		|  |  | 
	
		| UseAdditionalCode | codes for associated conditions 
 |  
		| Excludes1 | histiocytosis X (chronic) (C96.6) 
 |  | 
|  |  | 
	
		|  E88.0 |  | Disorders of plasma-protein metabolism, not elsewhere classified |  
		|  |  | 
	
		| Excludes1 | monoclonal gammopathy (of undetermined significance) (D47.2) polyclonal hypergammaglobulinemia (D89.0)
 Waldenström macroglobulinemia (C88.00)
 
 |  
		| Excludes2 | disorder of lipoprotein metabolism (E78.-) 
 |  |  |  |  | 
	
		|  E88.01 |  | Alpha-1-antitrypsin deficiency |  
		|  |  |  |  |  |  |  | 
	
		|  E88.02 |  | Plasminogen deficiency |  
		|  |  | 
| Dysplasminogenemia |  | Hypoplasminogenemia |  | Type 1 plasminogen deficiency |  | Type 2 plasminogen deficiency |  
		| CodeAlso | , if applicable, ligneous conjunctivitis (H10.51-) 
 |  
		| UseAdditionalCode | code for associated findings, such as: hydrocephalus (G91.4)
 otitis media (H67.-)
 respiratory disorder related to plasminogen deficiency (J99)
 
 |  |  |  |  |  | 
	
		|  E88.09 |  | Other disorders of plasma-protein metabolism, not elsewhere classified |  
		|  |  |  |  |  | 
|  |  | 
	
		|  E88.1 |  | Lipodystrophy, not elsewhere classified |  
		|  |  | 
	
		| Excludes1 | Whipple's disease (K90.81) 
 |  |  |  |  | 
	
		|  E88.10 |  | Lipodystrophy, unspecified |  
		|  |  |  |  |  |  |  | 
	
		|  E88.11 |  | Partial lipodystrophy |  
		|  |  | 
| Acquired partial lipodystrophy (APL) |  | Barraquer-Simons lipodystrophy |  | Familial partial lipodystrophy (FPLD) |  |  |  |  |  | 
	
		|  E88.12 |  | Generalized lipodystrophy |  
		|  |  | 
| Acquired generalized lipodystrophy (AGL) |  | Berardinelli-Siep syndrome |  | Congenital generalized lipodystrophy (CGL) |  | Lawrence syndrome |  |  |  |  |  | 
	
		|  E88.13 |  | Localized lipodystrophy |  
		|  |  | 
| Injection lipodystrophy |  | Insulin lipodystrophy |  |  |  |  |  | 
	
		|  E88.14 |  | HIV-associated lipodystrophy |  
		|  |  | 
	
		| CodeFirst | any human immunodeficiency virus [HIV] disease (B20) 
 |  
		| UseAdditionalCode | code for adverse effect, if applicable, to identify drug (T37.5X5-) 
 |  |  |  |  |  | 
	
		|  E88.19 |  | Other lipodystrophy, not elsewhere classified |  |  | 
|  |  | 
	
		|  E88.2 |  | Lipomatosis, not elsewhere classified |  
		|  |  | 
| Lipomatosis NOS |  | Lipomatosis (Check) dolorosa [Dercum] |  |  | 
|  |  | 
	
		|  E88.3 |  | Tumor lysis syndrome |  
		|  |  | 
| Tumor lysis syndrome (spontaneous) |  | Tumor lysis syndrome following antineoplastic drug chemotherapy |  
		| UseAdditionalCode | code for adverse effect, if applicable, to identify drug (T45.1X5) 
 |  |  | 
|  |  | 
	
		|  E88.4 |  | Mitochondrial metabolism disorders |  
		|  |  | 
	
		| Excludes1 | disorders of pyruvate metabolism (E74.4) Kearns-Sayre syndrome (H49.81)
 Leber's disease (H47.22)
 Leigh's encephalopathy (G31.82)
 Mitochondrial myopathy, NEC (G71.3)
 Reye's syndrome (G93.7)
 
 |  |  |  |  | 
	
		|  E88.40 |  | Mitochondrial metabolism disorder, unspecified |  |  |  |  | 
	
		|  E88.41 |  | MELAS syndrome |  
		|  |  | 
| Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes |  |  |  |  |  | 
	
		|  E88.42 |  | MERRF syndrome |  
		|  |  | 
| Myoclonic epilepsy associated with ragged-red fibers |  
		| CodeAlso | progressive myoclonic epilepsy (G40.3-) 
 |  |  |  |  |  | 
	
		|  E88.43 |  | Disorders of mitochondrial tRNA synthetases |  
		|  |  | 
| ARS2-related mitochondrial disorders |  | LBSL |  | Leukoencephalopathy with brainstem - spinal cord involvement - lactate elevation |  | Leukoencephalopathy with thalamus - brainstem involvement - high lactate |  | LTBL |  | Mitochondrial aminoacyl-tRNA synthetase disorders |  
		| CodeAlso | , if applicable, associated condition such as: leukoencephalopathy (G93.49)
 
 |  |  |  |  |  | 
	
		|  E88.49 |  | Other mitochondrial metabolism disorders |  |  | 
|  |  | 
	
		|  E88.8 |  | Other specified metabolic disorders |  |  |  | 
	
		|  E88.81 |  | Metabolic syndrome and other insulin resistance |  
		|  |  | 
	
		| UseAdditionalCode | codes for associated manifestations, such as: obesity (E66.-)
 
 |  |  |  |  | 
	
		|  E88.810 |  | Metabolic syndrome |  
		|  |  |  |  |  |  |  | 
	
		|  E88.811 |  | Insulin resistance syndrome, Type A |  |  |  |  | 
	
		|  E88.818 |  | Other insulin resistance |  
		|  |  | 
| Insulin resistance syndrome, Type B |  |  |  |  |  | 
	
		|  E88.819 |  | Insulin resistance, unspecified |  |  |  |  |  | 
	
		|  E88.82 |  | Obesity due to disruption of MC4R pathway |  
		|  |  | 
	
		| UseAdditionalCode | code, if applicable, to identify associated manifestations, such as polyphagia (R63.2) 
 |  
		| UseAdditionalCode | code to identify body mass index (BMI), if known (Z68.-) 
 |  |  |  |  |  | 
	
		|  E88.89 |  | Other specified metabolic disorders |  
		|  |  | 
| Launois-Bensaude adenolipomatosis |  
		| Excludes1 | adult pulmonary Langerhans cell histiocytosis (J84.82) 
 |  |  |  | 
|  |  | 
	
		|  E88.9 |  | Metabolic disorder, unspecified |  | 
|  |  | 
	
		|  E88.A |  | Wasting disease (syndrome) due to underlying condition |  
		|  |  | 
| Cachexia due to underlying condition |  
		| CodeFirst | underlying condition 
 |  
		| Excludes1 | cachexia NOS (R64) nutritional marasmus (E41)
 
 |  
		| Excludes2 | failure to thrive (R62.51, R62.7) 
 |  |  |